EnaVate Sciences is a biopharmaceutical company focused on developing innovative therapies for patients with immunological diseases. The company leverages its proprietary R&D platform to discover and advance mid-to-late-stage clinical development programs.

Enavate Sciences is a platform dedicated to supporting therapeutic companies advancing medicines and enabling technologies with transformative potential to address patient need. Through the application of capital support and operational experience, Enavate strives to enable and empower a diverse portfolio of therapeutics companies to accelerate innovation. To learn more about Enavate, please visit www.enavatesciences.com. 

Patient Square Capital

Enavate Sciences

Sionna Therapeutics announced this morning that it has raised $182 million in Series C financing led by Enavate Sciences alongside new and existing investors. The funding will help advance the clinical development of a novel small molecule treatment for cystic fibrosis. Enavate’s Edd Fleming will join Sionna Therapeutics’s Board as a part of the transaction. Read the announcement here: https://lnkd.in/gsGC__-7
#therapeutics #healthcare #investing #CysticFibrosis

Health care finance veteran Christine Del Corsano has joined our leadership team as Chief Financial Officer. With fifteen years of recent leadership experience in finance and operations in health care investment banking, Christine will lead finance and operations at Enavate as we advance and execute our strategic plan. Read the announcement here: https://lnkd.in/eHXucqvC  #healthcare #privateequity

ICYMI - Earlier this week, Enavate Sciences supported Graviton Bioscience in its latest financing round. The funding will advance Graviton’s pipeline of drug candidates and ROCK2 therapies to treat a range of fibrotic, inflammatory, and neurologic conditions. Read the full announcement here: https://lnkd.in/e7bdC_yV 

#Therapeutics #Healthcare #Investing  

Enavate Sciences supports Graviton Bioscience in its latest financing round together with Cormorant Asset Management, LP, Pontifax Venture Capital and Ovid Therapeutics. Representing our eighth portfolio investment in partner companies to date, this additional funding will advance Graviton’s pipeline of drug candidates and ROCK2 therapies to treat a range of fibrotic, inflammatory, and neurologic conditions.

Read the announcement here: https://lnkd.in/etXG3Urs 

#therapeutics #healthcare #investing  

Sudo Biosciences has raised $116M in Series B financing, co-led by Enavate Sciences and TPG Life Sciences Innovation. The investment will help advance the development of two new TYK2 inhibitors, with the aim of improving health outcomes for patients with severe autoimmune and neuroinflammatory conditions including multiple sclerosis, Alzheimer’s disease, and amyotrophic lateral sclerosis (ALS). Read the announcement here:  https://lnkd.in/edgkg4dg #therapeutics #healthcare #investing #biopharmaceuticals  

COM:ENAVATESCIENCES

EnaVate Sciences

Analysis Not Available